Report top-line results from batoclimab pivotal trial in myasthenia gravis
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 6 Feb 2025
- Due
- 31 Mar 2025
- Delivered
- 19 Mar 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Immunovant intends to report top-line results from the pivotal trial of batoclimab in MG by March 31, 2025.”
What we found
Evidence strength A What the grades mean
Immunovant reported positive topline Phase 3 batoclimab MG results on March 19, 2025, before the March 31, 2025 deadline.
-
A SEC Exhibit 99.1 - Immunovant Announces Positive Results SEC filing confirming topline MG results reported March 19, 2025
-
B Immunovant Announces Positive Results for Batoclimab MG and CIDP Studies Company press release reporting topline Phase 3 MG results met primary endpoint
Checked 12 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Language
- Aspirational (“aims”, “intends”)
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Immunovant, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-IMVT-000320 · Corrections policy